Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro and in vivo evaluation

1. A. J. Wein and E. S. Rovner, Definition and epidemiology of overactive bladder, Urology60 (2002) 7–12; DOI: 10.1016/S0090-4295(02)01784-3.10.1016/S0090-4295(02)01784-3Search in Google Scholar

2. S. Tyagi, C. A. Thomas, Y. Hayashi and M. B. Chancellor, The overactive bladder: epidemiology and morbidity, Urol. Clin. North Am.33 (2006) 433–438; DOI: 10.1016/j.ucl.2006.06.002.10.1016/j.ucl.2006.06.002Search in Google Scholar

3. H. Hashim and P. Abrams, Drug treatment of overactive bladder: Efficacy, cost and quality-of-life considerations, Drugs64 (2004) 1643–1656; DOI: 10.2165/00003495-200464150-00003.10.2165/00003495-200464150-00003Search in Google Scholar

4. F. Haab, L. Stewart and P. Dwyer, Darifenacin, an M₃ selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder, Eur. Urol.45 (2004) 420–429; DOI: 10.1016/j.eururo.2004.01.008.10.1016/j.eururo.2004.01.008Search in Google Scholar

5. P. K. Kiptoo, M. O. Hamad, P. A. Crooks and A. L. Stinchcomb, Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion, J. Control. Release113 (2006) 137–145; DOI: 10.1016/j.jconrel.2006.04.003.10.1016/j.jconrel.2006.04.003Search in Google Scholar

6. K. Maman, S. Aballea, J. Nazir, K. Desroziers, M. E. Neine, E. Siddiqui, I. Odeyemi and Z. Hakimi, Comparative efficacy and safety of medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison, Eur. Urol.65 (2014) 755–765; DOI: 10.1016/j.eururo.2013.11.010.10.1016/j.eururo.2013.11.010Search in Google Scholar

7. T. Omotosho and C. C. G. Chen, Update on tolterodine extended-release for treatment of overactive bladder, Open Access J. Urol. (2010) 185–191; DOI: 10.2147/OAJU.S7232.10.2147/OAJU.S7232Search in Google Scholar

8. P. Rama Rao, M. N. Reddy, S. Ramakrishna and P. V Diwan, Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits, Eur. J. Pharm. Biopharm.56 (2003) 81–85; DOI: 10.1016/S0939-6411(03)00038-9.10.1016/S0939-6411(03)00038-9Search in Google Scholar

9. D. Clemett and B. Jarvis, Tolterodine: a review of its use in the treatment of overactive bladder, Drugs Aging18 (2001) 277–304.Search in Google Scholar

10. D. Gautam, T. S. Heard, Y. Cui, G. Miller, L. Bloodworth and J. Wess, Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice, Mol. Pharmacol.66 (2004) 260–267; DOI: 10.1124/mol.66.2.260.10.1124/mol.66.2.26015266016Search in Google Scholar

11. A. Arora, E. Kisak, P. Karande, J. Newsam and S. Mitragotri, Multicomponent chemical enhancer formulations for transdermal drug delivery: more is not always better, J. Control. Release144 (2010) 175–180; DOI: 10.1016/j.jconrel.2010.02.015.10.1016/j.jconrel.2010.02.01520153789Search in Google Scholar

12. V. W. Nitti, S. Sanders, D. R. Staskin, R. R. Dmochowski, P. K. Sand, S. MacDiarmid and H. I. Maibach, Transdermal delivery of drugs for urologic applications: Basic principles and applications, Urology67 (2006) 657–664; DOI: 10.1016/j.urology.2005.11.039.10.1016/j.urology.2005.11.03916618554Search in Google Scholar

13. M. Akhlaq, M. S. Arshad, A. M. Mudassir, A. Hussain, I. Kucuk, R. Haj-Ahmad, M. Rasekh and Z. Ahmad, Formulation and evaluation of anti-rheumatic dexibuprofen transdermal patches: a quality-by-design approach, J. Drug Target.24 (2016) 603–612; DOI: 10.3109/1061186X.2015.1116538.10.3109/1061186X.2015.111653826586147Search in Google Scholar

14. L. Zhao, Y. Li, L. Fang, Z. He, X. Liu, L. Wang, Y. Xu and C. Ren, Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation, Int. J. Pharm.374 (2009) 73–81; DOI: 10.1016/j.ijpharm.2009.03.005.10.1016/j.ijpharm.2009.03.00519446762Search in Google Scholar

15. F. Sun, C. Sui, Y. Zhou, X. Liu, Y. Shi, Y. Wu and Y. Li, Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder, Int. J. Pharm.454 (2013) 532–538; DOI: 10.1016/j.ijpharm.2013.07.041.10.1016/j.ijpharm.2013.07.04123891744Search in Google Scholar

16. A. H. Elshafeey, A. O. Kamel and M. M. Fathallah, Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies, Pharm. Res.26 (2009) 2446–2453; DOI: 10.1007/s11095-009-9956-5.10.1007/s11095-009-9956-519697106Search in Google Scholar

17. R. Rajabalaya, S. R. David, J. Chellian, G. Xin Yun and S. Chakravarthi, Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder, Drug Deliv.23 (2016) 1578–1587; DOI: 10.3109/10717544.2015.1116027.10.3109/10717544.2015.111602726634274Search in Google Scholar

18. R. Rajabalaya, G. Leen, J. Chellian, S. Chakravarthi and S. David, Tolterodine tartrate proniosomal gel transdermal delivery for overactive bladder, Pharmaceutics8 (2016) 27; DOI: 10.3390/pharmaceutics8030027.10.3390/pharmaceutics8030027503944627589789Search in Google Scholar

19. R. Rajabalaya, S. R. N. David, J. Khanam and A. Nanda, Studies on the effect of plasticizer on in vitro release and ex vivo permeation from Eudragit E 100 based chlorpheniramine maleate matrix type transdermal delivery system, J. Excipients Food Chem.1 (2010) 3–12.Search in Google Scholar

20. S. R. N. David, M. S. Hui, C. F. Pin, F. Y. Ci and R. Rajabalaya, Formulation and in vitro evaluation of ethosomes as vesicular carrier for enhanced topical delivery of isotretinoin, Int. J. Drug Deliv.5 (2013) 28–34.Search in Google Scholar

21. T. Oki, A. Toma-Okura and S. Yamada, Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion, J. Pharmacol. Exp. Ther.316 (2006) 1137–1145; DOI: 10.1124/jpet.105.094508.10.1124/jpet.105.09450816282521Search in Google Scholar

22. R. Rajabalaya, S. R. N. David, J. Khanam and A. Nanda, Effect of platicizers on in vitro release and ex vivo permeation of chlorpheniramine maleate from ethyl cellulose polyvinyl pyrrolidone based matrix patches, Farmacia61 (2013) 975–990.Search in Google Scholar

23. S. David, R. Rajabalaya and E. Zhia, Development and in vitro evaluation of self-adhesive matrix-type transdermal delivery system of ondansetron hydrochloride, Trop. J. Pharm. Res.14 (2015) 211–218; DOI: 10.4314/tjpr.v14i2.4.10.4314/tjpr.v14i2.4Search in Google Scholar

24. R. Rajabalaya, J. Khanam and A. Nanda, Design of a matrix patch formulation for long-acting permeation of diclofenac potassium, Asian J. Pharm. Sci.3 (2008) 30–39.Search in Google Scholar

25. R. Rajabalaya, T. W. Xian and S. R. N. David, Preparation and evaluation of transdermal drug delivery of ondansetron hydrochloride: effect of vegetable oils as permeation enhancer, Lat. Am. J. Pharm.31 (2012) 1005–1012.Search in Google Scholar

26. R. Rajabalaya, H. Q. Choo and S. R. N. David, Development and in vitro evaluation of matrix type transdermal delivery of ondansetron hydrochloride, Int. J. Drug Deliv.4 (2012) 125–133.Search in Google Scholar

27. J. Siepmann, F. Lecomte and R. Bodmeier, Diffusion-controlled drug delivery systems: calculation of the required composition to achieve desired release profiles, J. Control. Release60 (1999) 379–389.Search in Google Scholar

28. K. Ghosal, A. Chandra, R. Rajabalaya, S. Chakraborty and A. Nanda, Mathematical modeling of drug release profiles for modified hydrophobic HPMC based gels, Pharmazie67 (2012) 147–155; DOI: 10.1691/ph.2012.1014.Search in Google Scholar

29. T. Oki, S. Maruyama, Y. Takagi, H. I. Yamamura and S. Yamada, Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice, Eur. J. Pharmacol.529 (2006) 157–163; DOI: 10.1016/j.ejphar.2005.11.004.10.1016/j.ejphar.2005.11.00416316647Search in Google Scholar